


Derazantinib dihydrochloride

Cat. No.:	HY-19981B
CAS No.:	1821329-75-2
Molecular Formula:	C ₂₉ H ₃₁ Cl ₂ FN ₄ O
Molecular Weight:	541.49
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Derazantinib (ARQ-087) dihydrochloride is an ATP competitive and orally active FGFR inhibitor (IC ₅₀ s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3). Derazantinib dihydrochloride inhibits FGFR phosphorylation. Derazantinib dihydrochloride inhibits tumor growth in multiple xenograft models ^{[1][2]} .
IC ₅₀ & Target	1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM ^[1]

REFERENCES

[1]. Hall TG, et al. Preclinical Activity of ARQ-087, a Novel Inhibitor Targeting FGFR Dysregulation. PLoS One. 2016 Sep 14;11(9):e0162594.

[2]. Balek L, et al. ARQ-087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3. Bone. 2017 Dec;105:57-66.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA